Scientists find possible new therapy for some patients with non-small cell lung cancer
OSUCCC – James researchers have found a potentially effective drug-combination approach to treating certain patients with non-small cell lung cancer (NSCLC)
Related Articles
Survey Dangerous gap in knowledge about pancreatic cancer among adults under age 50
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by the OSUCCC – James shows most people continue to…
Plenary lecturer: Human Breast Cell Atlas charts pathway from healthy tissue to cancer – SABCS Meeting News
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
FDA Considers Approval of TLX250-CDx in Kidney Cancer
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC…
European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Fred Hutch receives funding to advance Indigenous cancer health equity
Fred Hutch Cancer Center’s Lonnie A. Nelson, PhD; Jason Mendoza, MD, MPH; and Myra Parker, JD, MPH, PhD, were awarded a U19 cooperative agreement from…
AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants
$50,000 over one year for researchers that seek to stimulate creative approaches to translate basic research into new treatment options for kidney cancer.
Highlights of ASH in North America
Join the world’s leading hematology experts at Highlights of ASH in North America, a two-day program offered in multiple locations that highlights the most influential…
